Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Scleroderma renal crisis20.01.03.026; 15.06.01.017; 10.04.07.004; 24.08.08.0030.000262%Not Available
Enterovesical fistula20.03.01.021; 07.11.05.0090.000035%
Myasthenia gravis crisis17.05.04.007; 15.05.08.004; 10.04.05.0070.000087%Not Available
Placenta accreta18.05.02.0030.000052%Not Available
Microscopic polyangiitis20.05.01.017; 10.02.02.025; 24.12.04.0160.000035%Not Available
Placental infarction18.05.02.005; 24.04.12.0010.000070%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.000035%Not Available
Portal venous gas07.01.06.0330.000035%Not Available
Necrotising retinitis24.04.10.006; 06.04.06.0120.000087%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000129%Not Available
Acute polyneuropathy17.09.01.0030.000035%Not Available
Skin plaque23.03.03.0440.000164%Not Available
Foetal hypokinesia18.03.02.0150.000035%Not Available
Ligament pain15.07.02.0070.000035%Not Available
Respiratory tract inflammation22.02.07.0150.000035%Not Available
Autoimmune pancreatitis10.04.08.010; 07.18.01.0090.000087%Not Available
Subretinal fluid12.01.04.031; 06.09.03.0270.000052%Not Available
Distributive shock24.06.02.0220.000035%Not Available
Respiratory muscle weakness22.09.01.004; 17.05.03.017; 15.05.06.0030.000035%Not Available
Exposed bone in jaw15.02.04.0340.000087%Not Available
Systolic dysfunction02.04.02.0350.000087%Not Available
Spinal pain08.01.08.030; 17.10.01.020; 15.02.01.0080.000070%Not Available
Glucocorticoid deficiency14.11.01.037; 05.01.02.0110.000077%Not Available
Chronic graft versus host disease in skin23.07.04.022; 12.02.09.025; 10.02.01.0570.000070%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.000035%Not Available
Fulminant type 1 diabetes mellitus10.04.08.013; 14.06.01.013; 05.06.01.0130.000087%Not Available
Clear cell renal cell carcinoma16.08.02.004; 20.01.04.0080.000035%Not Available
Abdominal lymphadenopathy07.11.01.018; 01.09.01.0200.000140%Not Available
Large intestinal stenosis07.13.03.0040.000052%
Graft versus host disease in eye12.02.09.027; 10.02.01.058; 06.04.05.0280.000035%Not Available
The 32th Page    First    Pre   32 33 34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene